WAM
BLCM

Wealthspire Advisors (Maryland)’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-220
Closed -$7K – 2236
2019
Q1 		$7K Buy
+220
New +$7.35K ﹤0.01% 1712

Other funds holding BLCM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s BLCM Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 220 shares — an estimated $7K sold.

Wealthspire Advisors (Maryland) first reported a position in BLCM in Q1 2019 and held it in 1 quarter. The position peaked at $7K in Q1 2019. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 220 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $7K.
  • Wealthspire Advisors (Maryland) first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Bellicum Pharmaceuticals, Inc. position peaked at $7K in Q1 2019.
  • 79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.